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INTRODUCTION: GnRH analogues (GnRHa) are the treatment of choice in idiopathic 
central precocious puberty (CPP) thought the real benefit on height gain is unclear. Hence, 
defining their effect on near adult height (NAH) in girls with idiopathic CPP is the main 
study’s aim.  
METHODS: An observational longitudinal prospective descriptive study of a cohort 
formed by 500 girls included in the Spanish register diagnosed of idiopathic CPP between 
January 2008 and January 2019 has been carried out. Triptorelin 3.75mg have been 
monthly administered and the gap between NAH and TH is the primary outcome.  
RESULTS: Data at treatment’s cessation from 283 girls and at NAH from 132 girls is 
reported. The primary outcome’s mean and 95% confidence interval have been -
1,033±6.362 cm and -2.293-0.277 cm respectively.  
CONCLUSIONS: GnRHa are helpful in preserving the genetic growth potential as a non-
insignificant quantity of patients has reached a NAH close to their TH. 
RESUM 
INTRODUCCIÓ: Els anàlegs de la GnRH (aGnRH) són el tractament d’elecció en la 
pubertat precoç central idiopàtica (PPCI). El benefici real sobre l’estatura final és incert. 
L’objectiu principal de l’estudi és definir l’efecte dels aGnRH sobre la talla quasi final 
adulta en nenes amb PPCI.  
METODOLOGIA: Estudi observacional, descriptiu, longitudinal i prospectiu d’una 
cohort de 500 nenes incloses en el registre espanyol i diagnosticades de PPCI entre 
gener’2008 i gener’2019. S’ha administrat Triptorelina 3.75 mg mensualment i la 
diferencia entre la talla quasi final adulta i la talla diana n’és la variable principal.  
 
 
RESULTATS: Es reporten els resultats de 283 nenes al final del tractament i de 132 a 
talla quasi final adulta. La mitjana i l’interval de confiança al 95% de la variable principal 
són -1,033±6.362 cm i -2.293-0.277cm respectivament.  
CONCLUSIONS: Els aGnRH són útils en preservar el potencial genètic de creixement. 
Una quantitat significativa de pacients ha assolit una talla dins seva talla diana.  
RESUMEN 
INTRODUCCION: Los análogos de la GnRH (aGnRH) son el tratamiento de elección en 
la pubertad precoz central idiopática (PPCI). El beneficio real sobre la estatura final es 
incierto. El objetivo principal del estudio es definir su efecto sobre la talla casi final adulta 
en niñas con PPCI.  
METODOLOGIA: Estudio observacional, descriptivo, longitudinal y prospectivo de una 
cohorte de 500 niñas incluidas en el registro español y diagnosticadas de PPCI entre 
enero’2008 y enero’2019. Se ha administrado Triptorelina 3.75 mg mensualmente y la 
diferencia entre la talla casi final y la talla diana es la variable principal.  
RESULTADOS: Se presentan los resultados de 283 niñas al final del tratamiento y 132 
niñas en la talla casi final. La media y el intervalo de confianza al 95% de la variable 
principal son -1,033±6.362 cm y -2.293-0.277 cm respectivamente.  
CONCLUSIONES: Los aGnRH son útiles en preservar el potencial genético de 
crecimiento. Una cantidad significativa de pacientes alcanzan una talla final próxima a su 
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• BA: Bone age 
• BMI: Body mass index 
• CA: Chronological age 
• CPP: Central precocious puberty  
• FSH: Follicle-stimulating hormone 
• GnRH: Gonadotropin-releasing hormone 
• GnRHa: Gonadotropin-releasing hormone analogues 
• GV: Growth velocity 
• HPG axis: Hypothalamic pituitary gonadal axis 
• LH: Luteinizing hormone 
• NAH: Near adult height 
• PAH: Potential adult height 
• PP: Precocious puberty 
• SD: Standard deviation 
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1. INTRODUCTION       
1.1  THEORETICAL FRAMEWORK 
Puberty is a period in which so many physical, hormonal and psychological changes occur 
due to the hypothalamic-pituitary-gonadal (HPG) axis reactivation (Annexes: Figure 1). 
Gonadotropin-releasing hormone’s (GnRH) pulsatile hypothalamic secretion stimulates 
gonadotropin (LH – Luteinizing hormone and FSH – Follicle-stimulating hormone) 
excretion by anterior pituitary gland. As a consequence, the gonadal steroids (testosterone 
and estradiol) produced induce puberty changes (breast and testicular maturing, majora 
and minora labia enlargement, body fat increase and redistribution, cricoid cartilage 
growth, facia hair development, muscle mass increase, growth acceleration…). However, 
this is a multifactorial process influenced by genetic, environmental, ethnic, metabolic, 
economic, geographic… factors (1,2).  
The development of secondary sexual characteristics (II breast development’s Tanner 
stage) before the age of 8 years or menarche before the age of 9 years in girls is named 
precocious puberty (PP). In the same way, the appearance of a testicular volume greater 
than 4 ml before the age of 9 years is considered PP in boys (1–5). It occurs in out 5000 
children, being 10 times more frequent in females than in males. According to its 
physiopathology, PP is classified in diferent categories (1,5–7):  
• Normal puberty’s variants such as isolated forms of premature telarche, pubarche or 
vaginal bleeding.  
• Peripheral PP: It is gonadotropin-independent as it is caused by a distrubance outside 
HPG axis like adrenal tumors, germ cells hCG secretory tumors, congenital adrenal 
hyperplasia, exogen source of gonadal or adrenal hormones… 
• Central precocious puberty (CPP): It is the most frequent one and it is a consequence 
of an early HPG axis reactivacion due to diferent causes (Annexes: Table 1). The 
3 
idiopathic form is the most common one, being approximately the 90% in girls and 
the 70% in boys.  
The premature sex steroid hormone’s secretion that takes place in PP advances the 
secondary sexual characteristics’ progression and increases growth velocity, driving to an 
early fusion of the long bones’ epiphyseal growth plates, resulting in a short stature in 
comparison with the genetic potential. Besides, this can lead to psychosocial 
maladjustment (2,4,5,7,8).  
GnRH analogues (GnRHa) are the treatment of choice since 1980s in children with CPP 
(4,7–10). This synthetic decapeptide derives from a chemical substitution of the native 
molecule, which increases its resistance to enzymatic degradation (2). They compete with 
GnRH endogenous for its receptor in the anterior pituitary gland, promoting its 
endocytosis and producing a receptor down-regulation (1). Thus, GnRHa administered 
chronically suppress sexual hormones’ production, reducing growth velocity (GV) and 
giving to the long bones more time to lengthen before epiphyseal fusion. As a result, the 
bone age (BA) is progressively normalized and the linear growth continues, so children 
with CPP can achieve an adult height according with their genetics (4,6,7,11,12). Perhaps, 
the treatment’s main aims are interrupting sexual maturation until pubertal age, stabilizing 
the sexual secondary characteristics, restoring genetic height potential by delaying 
skeletal maturation and preventing psychological problems (1,3,9). Depot subcutaneous 
formulations monthly or trimonthly administered are the preferred ones because of the 
better patient’s compliance. Nevertheless, a prolonged action subdermal implants are 
available too, even though their use is still controversial (1,2,10,13). Moreover, GnRHa 
are generally well tolerated, being the local adverse effects related to its injection such as 
allergic reactions or sterile abscess the most frequent ones. Headache, abdominal pain, 
vaginal bleeding after the first dose and vasomotor symptoms have been also described, 
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as well as anaphylaxis, which is extremely rare (1,2,10,13). In addition, body mass 
index’s (BMI) transitional changes and a polycystic ovary syndrome prevalence’s 
increase have been revealed despite the evidence is not conclusive (3,11,14,15).  
In relation to the studies made in children, progressive PP forms (defined as the 
progression from one Tanner stage to another in less than six months and a GV above 6 
cm/year), a predicted adult height (PAH) below 2.5 percentile or below target height 
(TH), a height’s standard deviation (SD) below -2 or a PAH loss during a follow up period 
are treatment indications, as evidence has shown a GnRHa benefit in preserving the 
genetic height potential, mainly in those girls who had started the treatment before the 
age of 6 (1,2,11–13,16). On the contrary, results in older children and in non-progressive 
or slowly progressive PP are not highly convincing. Similarly, no benefits in height gain 
have been demonstrated in early puberty (defined as pubertal development between 8 and 
9 years in girls) (1,2,11,15,16).  
1.2  STUDY’s JUSTIFICATION 
The evidence, which is rich in girls but sparse in boys, seems to demonstrate a GnRHa 
favorable effect on stature growth thought the net height gain, the effect on BMI or the 
moment when treatment should be stopped remain debated. These uncertainties come 
from the lack of large sample sizes prospective studies and randomized control trials in 
this filed. Besides, historical cohorts reported decades ago are the control group in some 
studies which also include a low number of subjects and have some methodological 
limitations (1,2,6,7,9,16,17). In conclusion, more studies are needed to assess the real 
GnRHa influence on height gain.  
1.3  OBJECTIVES and HYPOTESIS 
The present study’s main aim is to define GnRHa effect on near adult height (NAH) in 
girls with idiopathic CPP. In addition, describing the mean treatment duration, the 
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chronological age (CA) and the bone age (BA) at treatment’s cessation, the mean time 
until menarche after therapy’s stop, the growth and BMI evolution and the adverse effects 
registered are the secondary objectives. In conclusion, the study’s hypothesis is that 
GnRHa have a beneficial effect on NAH in girls with idiopathic CPP.  
2. METHODS 
2.1  STUDY’s DESIGN 
This is an observational longitudinal prospective descriptive study of a cohort formed by 
500 girls from 55 Spanish centers diagnosed of idiopathic CPP and included in the 
Spanish register (www.seep.es/pubere) between January 2008 and 31st January 2019.   
2.2  PARTICIPANTS 
The inclusion criteria are female sex, the presence of progressive thelarche before 8 years 
of age, a LH peak more than 7 U/L in LHRH stimulation test (100µg/m2), a difference 
between BA and CA of more than 1 year and a normal cranial image. On the contrary, 
early puberty forms and CPP with an identified etiology are the exclusion criteria.  
2.3  INTERVENTIONS and FOLLOW-UP 
Girls included have been treated with Triptorelin (GnRHa) 3,75 mg monthly 
administered, adjusting dose, if necessary, according to LHRH test and evolution. 
Besides, the follow-up has consisted in a visit and exploration of weight, height, BMI and 
secondary sexual characters every 6 months and an annually BA evaluation until girls 
have reached NAH.  
2.4  STUDY’s SIZE 
Study’s size has not been calculated before starting in order to achieve the maximum size 
possible, guaranteeing more reliable results than previous researches, which included a 
low number of patients. Because of that, inclusion criteria have been applied in Spanish 
6 
Register database, selecting all the girls who have achieved them. Consequently, the 
current study’s size is 500 girls.   
2.5  RISK OF BIAS  
In relation to the risk of bias, having no control group for ethical reasons can lead to a 
selection bias, because of the comparison with historical cohorts. Moreover, an aleatory 
error is present as in any study, but the fact of comprising a high number of patients 
decreases its relevance. Finally, overweight at diagnosis and the adoption are CPP’s risk 
factors, being able to act as confounding factors (1–3,11,14,18,19).  
2.6  OUTCOMES 
According to the study’s aims, the difference between NAH and TH is the primary 
outcome. Moreover, secondary outcomes are the gap between NAH and PAH (an 
important variable in adopted girls whose genetical potential is unknown), NAH and its 
standard deviation (SD), the mean treatment duration, the mean time until menarche after 
treatment cessation’s, the BA and the CA at those moment and the difference between 
height at GnRHa’s withdrawal and NAH. Ultimately, BMI evolution during therapy is 
also a secondary end-point.  
2.7  OUTCOMES’ MEASURES  
Height, NAH, TH and PAH are expressed in centimeters as well as their standard 
deviations, which have been determined for age and sex in relation to Spanish children 
population (20). Girls TH has been calculated by subtracting 6.5 cm from the average 
parental height whereas PAH has been obtained by Bayley and Pinneau method (21).  
Likewise, the BA has been assessed using a left hand X-ray and comparing it with the 
standards, following Greulich and Pile method (21,22). Furthermore, NAH has been 
measured in girls achieving a BA of more than 15 years or a GV less than 2 
centimeters/year if menarche has occurred. The treatment duration and the time between 
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treatment’s stop and menarche are expressed in months while the BA and the CA are 
described in years. Furthermore, secondary sexual characteristics like breast development 
have been evaluated by a physical exploration and in accordance with Tanner pubertal 
staging (Annexes: Table 2)(23). At last, weight (Kg) and BMI (weight (Kg)/height(cm)2) 
have been also determined and compared with Spanish children population (20).  
2.8  STATISTICAL ANALYSIS  
Data related to subject’s baseline characteristics and study’s outcomes has been collect 
using this computer database (www.seep.es/pubere). The normal distribution of the 
baseline characteristics has been apprised observing the histogram’s symmetry (Fisher 
coefficient) and kurtosis (g2 coefficient) and the difference between the mean and the 
median. In addition, data has been analyzed by SPSS.25 software. Quantitative outcomes 
are expressed by their mean, median, minimum, maximum, SD and the 95% confidence 
interval. Otherwise, qualitative variables are represented by their frequencies.  
2.9  ECONOMICAL AND ETHICAL ASPECTS 
The current study has been approved by Ethics Committee of clinical investigation 
(Ethics Committee of the Spanish Society for Pediatric Endocrinology (SEEP)) and 
patient anonymity and personal information have been always protected following 
Helsinki Declaration. It does not dispose of a control group because of ethical reasons, as 
the evidenced GnRHa’s benefit in height gain. Due to its design, it does not involve any 






3.1  FLOWCHART  
SEEP register includes 547 girls diagnosed by PP, but only 500 of them reach the study’s 
inclusion criteria. Results are reported at the end of treatment (n=283) and at NAH 
(n=132) (Annexes: Figure 2).    
3.2  BASELINE CHARACTERISTICS  
The study’s patients baseline characteristics are summarized in Annexes (Table 3, Figure 
3 and 4). There is a 18% of adopted girls, a 11.6% of immigration and a 68,8% of 
Caucasian population (Annexes: Figure 3). The majority of the cohort lives in an urban 
residence (70,6%) and, in relation to the autonomous community (Annexes: Figure 4), 
most of them are from Catalunya (32.8%) and Community of Madrid (22.6%). Family 
background is present in 19.6% of cases, being unknown in 26,8% of girls. The mean CA 
and BA at diagnosis is 7,15 ± 1,083 (n=477) and 9,2 ± 1,387 (n=471) years respectively, 
with an average difference between them of 2,054 ± 0,896 (n=471) years. Moreover, the 
most frequent Tanner Stages at diagnosis are Stage II (63,4%) and III (28,8%). 
Furthermore, the average patients’ TH is 159,47 ± 5,174 cm (n=389), being its SD -0.31 
± 0,904 cm (n=389). However, 128,25 ± 8,926 cm (n=473) is the mean height at 
diagnosis, with an SD of 1,59 ± 1,288 cm (n=473), whereas PAH is 160,29 ± 8,518 cm 
(n=442). In relation to BMI, its diagnosis value is 17,75 ± 2,418 (n=473) and its SD is 
0,51 ± 1,165 (n=473).  
3.3  OUTCOMES’ RESULTS 
Study’s outcomes statistical analysis is represented in Table 4 (Annexes).  
As for primary end-point, the mean difference between NAH and TH and between their 
SDs has been -1,033 ± 6.362 cm (n=102) and -0,178 ± 1,112 cm (n=102), respectively. 
In the same way, results show a negative difference between NAH and PAH (mean of -
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3,093 ± 7,012 cm, n=126) as well as between their SDs (mean of -0,54 ± 1,225 cm, 
n=126). In addition, the average NAH and NAH’s SD has been 156,48 ±7,073 cm 
(n=132) and -0,822 ± 1,236 cm (n=132).  
Besides, treatment’s cessation has occurred with a CA of 10,03 ± 1,004 years (n= 283) 
and a BA of 11,67 ± 0,793 years (n=240). Thus, the mean treatment’s duration has been 
29,82 ± 14,21 months (n=282) while the average time until menarche has been 13,14 ± 
9,74 months (n=210).  
Figure 5 (Annexes) and 6 (Annexes) show height expressed in centimeters and SD at 
treatment’s start, at treatment’s end and at NAH. Related to that, a notable height increase 
has been seen during the therapy and after its cessation, with a mean difference between 
height at GnRHa’s stop and NAH of 11,27 ± 4,896 cm (n=130). Similarly, a height’s SD 
gap between both moments of 1,98 ± 0,871 cm (n=130) has been present. Moreover, 
Figure 7 (Annexes) represents height’s continuous evolution, confirming a progressive 
stature rise with GnRHa and until NAH.  
Along with BMI’s SD, its average value at treatment’s ending and at NAH has been 1,089 
± 1,277 (n=283) and 0,925 ± 1,249 (n=124). Briefly, as Figure 8 (Annexes) demonstrates, 
a BMI’s SD increment have occurred between the therapy’s start and suspension even 
though it after has decreased until NAH.  
Finally, a 3.4% (n=17) of girls have suffered adverse effects, such as spotting after the 
first GnRHa dose (1.2%, n=6), vaginal bleeding following treatment’s cessation (0.6%, 
n= 3), headache (0.6%, n= 3), hair loss (0.6%, n=3), local pain at injection’s point (0.2%, 
n=1), emotional lability (0.2%, n=1) and vasomotor symptoms (0.2%, n=1).  
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4. DISCUSSION  
The most relevant strength of this study is its large sample size, being the first research 
including such a huge cohort of girls with idiopathic CPP. In addition, it has provided 
information about GnRHa and PP in the Spanish population, which had hardly been 
investigated before. Moreover, the NAH comparison with TH instead of with PAH avoids 
the PAH’s overestimation that takes in CPP, especially in those patients whose skeletal 
maturation is markedly advanced. Besides, the number of subjects evaluated at NAH is 
relatively small as to the number initially included. To put it in another way, there are 
several patients being follow up whose analysis when NAH will occur will lead to 
stronger conclusions.  
The main debate about GnRHa therapy has concerned on whether they could have a great 
benefit on NAH, which is compromised in CPP. Because of that, the main study’s 
objective has been describing GnRHa’s effect on height gain by the difference between 
NAH and TH (or PAH in adopted girls) as a primary variable. According to it, although 
its mean value is a negative one  (-1.033 ±6.362 cm), its confidence interval (IC 95% -
2.293 – 0.227), its minimum and maximum and the ±5 cm of error that could take place 
when calculating PAH demonstrate that a non-insignificant quantity of subjects have 
achieved and overtook their TH, not differing from what happened in other cohorts 
(2,4,7,15–17). For instance, Bereket et.al obtained a mean NAH 1 cm shorter than TH, 
concluding that GnRHa may not be capable to restore a full genetic height potential when 
treatment had been started after a certain critical advancement BA. However, they 
concluded that a difference of 1 cm is not clinically relevant, because it could be related 
to so many influences (9). Perhaps, the results support our hypothesis about the beneficial 
GnRHa’s effect on the growth. In relation to height evolution (Annexes: figure 5, 6 and 
7), the study’s findings denote a significant difference between the value at diagnosis, at 
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treatment’s cessation and NAH. Historical series of untreated patients reported an average 
NAH of 152 cm in girls (2,3,7). Despite these data should be interpreted cautiously 
because of studies’ limitations, a higher NAH and NAH’s SD has been revealed in the 
current research. Additionally, there has been an increment between height at GnRHa 
withdrawal and NAH, highlighting the importance of stopping the therapy at a specific 
time, giving to the bones enough time to continue growing.  
In terms of the BA and the CA at GnRHa’s ending, Guaraldi et.al obtained an average 
CA and BA of 11.1 years (IC 95%: 9.4 – 12.7) and 12.4 years (IC 95%: 11.9 – 13.6) 
respectively, values which differ a bit from ours (2). Likewise, a mean treatment duration 
of 29.82 ±14.21 months (IC 95 % 28.13-31.51) is reported whereas Guaraldi et.al 
described a 3 year one (2). Besides, 13.14 ± 9.74 months (IC 95% 11.79 – 14.48) has 
been described between GnRHa’s cessation and menarche, close to Guaraldi et.al and 
other observational studies in whose menstruation occurred on average after 12-16 
months (IC 95% 2-60)(1,2,11).  
As far as BMI is concerned, overweight has been associated with CPP (1,4,18) and 
historical cohorts and clinical controlled trials have found a BMI increase during therapy, 
although it has usually normalized thereafter (2,11,15,24). However, some research have 
postulated that this condition may persist afterwards (11,14). In accordance with the 
present study, BMI SD at diagnosis has been over reference population and a higher one 
has been observed at treatment’s cessation, not being significantly different from the one 
at NAH. Above all, GnRHa’s influence on this outcome is still controversial, although it 
does not seem to be a long-term effect in the majority of cases (2,24).  
Finally, treatment have been well tolerated and minor adverse effects have been registered 
as in previous investigations, despite the long-term ones like polycystic ovaries syndrome 
or infertility have not been reported.  
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Nevertheless, this study has some limitations. First of all, the lack of a control group for 
ethical reasons can have led to a selection bias as well as just including girls, because 
different factors may be at play in boys with CPP. Furthermore, the comparison with 
historical cohorts should be interpreted cautiously, because of the possible differences 
related to baseline characteristics, the small sample size, the inclusion criteria… In the 
third place and even thought the most studies’ primary end-point is the difference between 
NAH and TH, this is not free of biases, because the midparental TH calculation assumes 
equal contribution of each parents’ heights, neglecting the impact of dominant genes from 
one of them (9). Finally, several confounding factors such as overweight or adoption 
could influence GnRHa’s effect on height gain (1–3,11,14,18,19).  
5. DIFUSSION PLAN 
This study is going to be continued following up the girls who are actually registered in 
the database and including new patients diagnosed of CPP if they achieve the inclusion 
criteria. Moreover, results are going to be actualized every 5 years and presented in 
SEEP’s congresses. At last, data is going to be published when more than 200 girls have 
reached NAH.  
6. CONCLUSIONS 
To summarize, the present study’s results suggest that GnRHa therapy is helpful in 
reaching a NAH close to the TH and PAH, being beneficial in preserving the genetic 




Firstly, I am grateful to Raquel Corripio for having tutorized my final degree project, 
always disposed to help me in whatever I have needed. Secondly, I thank to Joan Carles 
Oliva (Statistic of Parc Tauli Hospital) for his collaboration in the results analysis and to 























1.  Brito VN, Spinola-Castro AM, Kochi C, Kopacek C, Alves Da Silva PC, Guerra-
Júnior G. Central precocious puberty: revisiting the diagnosis and therapeutic 
management. Arch Endocrinol Metab [Internet]. 2016;60(2):163–72. Available 
from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-
39972016000200163&lng=en&tlng=en 
2.  Guaraldi F, Beccuti G, Gori D, Ghizzoni L. Long-term outcomes of the treatment 
of central precocious puberty. Eur J Endocrinol [Internet]. 2016;174(3):R79-87. 
Available from: https://eje.bioscientifica.com/view/journals/eje/174/3/R79.xml 
3.  Lee HS, Yoon JS, Roh JK, Hwang JS. Changes in body mass index during 
gonadotropin-releasing hormone agonist treatment for central precocious puberty 
and early puberty. Endocrine [Internet]. 2016;54(2):497–503. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27444748 
4.  Muratoğlu Şahin N, Uğraş Dikmen A, Çetinkaya S, Aycan Z. Subnormal Growth 
Velocity and Related Factors During GnRH Analog Therapy for Idiopathic Central 
Precocious Puberty. J Clin Res Pediatr Endocrinol [Internet]. 2018;10(3):239–46. 
Available from: http://cms.galenos.com.tr/Uploads/Article_17049/JCRPE-10-
239-En.pdf 
5.  Rohani F, Salehpur S, Saffari F. Etiology of precocious puberty, 10 years study in 
Endocrine Reserch Centre (Firouzgar), Tehran. Iran J Reprod Med [Internet]. 
2012;10(1):1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25242967 
6.  Liu S, Liu Q, Cheng X, Luo Y, Wen Y. Effects and safety of combination therapy 
with gonadotropin-releasing hormone analogue and growth hormone in girls with 
idiopathic central precocious puberty: a meta-analysis. J Endocrinol Invest 
[Internet]. 2016;39(10):1167–78. Available from: 
15 
http://link.springer.com/10.1007/s40618-016-0486-9 
7.  Li P, Li Y, Yang C-L. Gonadotropin releasing hormone agonist treatment to 
increase final stature in children with precocious puberty: a meta-analysis. 
Medicine (Baltimore) [Internet]. 2014;93(27):e260. Available from: 
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=0
0005792-201412020-00052 
8.  Lee PA. The effects of manipulation of puberty on growth. Horm Res [Internet]. 
2003;60(Suppl1):60–7. Available from: 
https://www.karger.com/Article/FullText/71228 
9.  Bereket A. A Critical Appraisal of the Effect of Gonadotropin-Releasing Hormon 
Analog Treatment on Adult Height of Girls with Central Precocious Puberty. J 
Clin Res Pediatr Endocrinol [Internet]. 2017;9(Suppl 2):33–48. Available from: 
http://cms.galenos.com.tr/Uploads/Article_16628/JCRPE-9-2-En.pdf 
10.  Silverman LA, Neely EK, Kletter GB, Lewis K, Chitra S, Terleckyj O, et al. Long-
Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants 
for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 
Multicenter Trial. J Clin Endocrinol Metab [Internet]. 2015;100(6):2354–63. 
Available from: https://academic.oup.com/jcem/article-
lookup/doi/10.1210/jc.2014-3031 
11.  Corripio R, Soriano-Guillén L, Herrero F-J, Cañete R, Castro-Feijoó L, Escribano 
A, et al. Changes in Body Mass Index in Girls with Idiopathic Central Precocious 
Puberty under Gonadotropin-Releasing Hormone Analogue Therapy: The Spanish 
Registry. Horm Res Paediatr [Internet]. 2016;86(3):154–60. Available from: 
https://www.karger.com/Article/FullText/448552 
12.  Shankar RR, Pescovitz OH. Precocious puberty. Adv Endocrinol Metab [Internet]. 
16 
1995;6:55–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7671102 
13.  Tuvemo T. Treatment of central precocious puberty. Expert Opin Investig Drugs 
[Internet]. 2006;15(5):495–505. Available from: 
https://www.tandfonline.com/doi/full/10.1517/13543784.15.5.495 
14.  Park J, Hwang TH, Kim Y-D, Han H-S. Longitudinal follow-up to near final height 
of auxological changes in girls with idiopathic central precocious puberty treated 
with gonadotropin-releasing hormone analog and grouped by pretreatment body 
mass index level. Ann Pediatr Endocrinol Metab [Internet]. 2018;23(1):14–20. 
Available from: http://e-
apem.org/journal/view.php?doi=10.6065/apem.2018.23.1.14 
15.  Chiavaroli V, Liberati M, D’Antonio F, Masuccio F, Capanna R, Verrotti A, et al. 
GNRH analog therapy in girls with early puberty is associated with the 
achievement of predicted final height but also with increased risk of polycystic 
ovary syndrome. Eur J Endocrinol [Internet]. 2010;163(1):55–62. Available from: 
https://eje.bioscientifica.com/view/journals/eje/163/1/55.xml 
16.  Lanes R, Soros A, Jakubowicz S. Accelerated versus slowly progressive forms of 
puberty in girls with precocious and early puberty. Gonadotropin suppressive 
effect and final height obtained with two different analogs. J Pediatr Endocrinol 
Metab [Internet]. 2004;17(5):759–66. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15237711 
17.  Chen S-K, Fan X, Tang Q. Impact of gonadotropin-releasing hormone analogs 
treatment on final height in girls with central precocious puberty. Zhongguo Dang 
Dai Er Ke Za Zhi [Internet]. 2009;11(5):374–6. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19470261 
18.  Neville KA, Walker JL. Precocious pubarche is associated with SGA, prematurity, 
17 
weight gain, and obesity. Arch Dis Child [Internet]. 2005;90(3):258–61. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/15723910 
19.  Virdis R, Street ME, Zampolli M, Radetti G, Pezzini B, Benelli M, et al. Precocious 
puberty in girls adopted from developing countries. Arch Dis Child [Internet]. 
1998;78(2):152–4. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/9579158 
20.  Hernández M, Castellet J, Narvaíza JL, Rincón JM, Ruíz I, Sánchez E, et al. 
CURVAS Y TABLAS DE CRECIMIENTO. Available from: 
https://www.fundacionorbegozo.com/wp-content/uploads/pdf/estudios_1988.pdf 
21.  Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised 
for use with the Greulich-Pyle hand standards. J Pediatr [Internet]. 
1952;40(4):423–41. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/14918032 
22.  Gilsanz V, Ratib O. Hand Bone Age: A Digital Atlas of Skeletal Maturity 
[Internet]. Available from: http://www.springeronline.com 
23.  Marshall WA, Tanner JM. Variations in Pattern of Pubertal Changes in Girls. Arch 
Dis Childh [Internet]. 1969. Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2020314/pdf/archdisch01552-
0003.pdf 
24.  Lazar L, Lebenthal Y, Yackobovitch-gavan M, Shalitin S, Vries L De, Phillip M, 
et al. Treated and Untreated Women With Idiopathic Precocious Puberty : BMI 
Evolution , Metabolic Outcome , and General Health Between Third and Fifth 





Figure 1: Chronology of sexual maturation and growth spurt during puberty in both 
genders according to Marshall & Tanner stages (1).  
 
Table 1: Central precocious puberty etiologies (1,5). 
CENTRAL PRECOCIOUS PUBERTY ETIOLOGIES 
         IDIOPATHIC 
GENETIC CAUSES Activating mutations in KISS1R and KISS1 genes 






Simple virializing congenital adrenal hyperplasia treated 
lately 
Following resection of sex steroid hormones secretory 
tumors 
Testoxicosis and McCune-Albright syndrome 
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 Pituitary tumors: astrocytoma, ependymoma, hypothalamic 
glioma, LH-secreting adenoma, pinealoma, neurofibroma, 
craniopharyngioma, etc. 
Congenital malformations: suprasellar cyst, arachnoid cyst, 
septo-optic dysplasia, spina bifida, vascular malformations, 
etc. 
Acquired diseases: inflammatory process (abscess, 
meningitis, encephalitis, sarcoidosis, tuberculosis), radiation, 
trauma, perinatal asphyxia. 
 
Table 2: Tanner Breast development stages (23).    
TANNER STAGE BREAST DEVELOPMENT 
Stage I Pre – adolescent; only papilla elevation. 
Stage II 
Breast bud stage; breast and papilla’ elevation as a small 
mound and areola diameter enlargement. 
Stage III 
Further breast and areola’ enlargement, with no separation of 
their contours. 
Stage IV 
Areola and papilla projection to form a secondary mound above 
the level of the breast. 
Stage V 
Mature stage; only papilla projection, because of areola 










n = 547 
Eligible participants 
n = 500 
 
Treatment finished 
n = 283 
Near adult height 
n = 132 
Participants excluded 
n = 47 
Followed – up 
n = 217 
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Table 3: Baseline characteristics 
Baseline characteristics N Frequency Mean + SD Median Minimum - maximum 
Adopted Adopted 90 18%  
Non - adopted 410 82 % 
Immigration Immigrant 58 11,6%  
Non – immigrant 442 88,4% 
Residence Urban residence 353 70,6  
Rural residence 147 29,4 
Family 
background 
Yes 98 19,6%  
No 268 53,6% 
Non-registered 134 26.8 % 
Tanner 
Stage 
Stage I 4 0,8  
Stage II 317 63,4 
Stage III 144 28,8 
Stage IV 7 1,4 
Stage V 1 0,2 
Stage non-registered 27 5,4 
Maternal height (cm) 394  160,15 ± 6,612 160 139 - 190 
Paternal height (cm) 390  171,80 ± 7,116 172,00 142 - 192 
Born height (cm) 321  48,93 ± 2,66 49,00 34 - 55 
Born weight (g) 394  3013,80 ± 562,753 3022,50 770 - 4900 
Target height (cm) 389  159,47 ± 5,175 159,5 141,25 – 174,50 
Target height SD (cm) 389  -0.31 ± 0,905 -0,31 -3,50 – 2.31 
Diagnosis CA (years) 477  7,15 ± 1,083 7,53 1,31 – 9,15 
Diagnosis BA (years) 471  9,2 ± 1,387 9 2,5 - 12 
Diagnosis BA – CA (years) 471  2,054 ± 0,896 1,96 -0,03 – 7,36 
Diagnosis height (cm) 473  128,25 ± 8,926 129,00 81,8 - 153 
Diagnosis height SD (cm) 473  1,59 ± 1,288 1,56 -1,74 – 10,48 
Diagnosis PAH (cm) 442  160,29 ± 8,518 160,63 133,41 – 189,33 
Diagnosis BMI 473  17,75 ± 2,418 17,37 12,37 – 32,83 
Diagnosis BMI SD 473  0,51 ± 1,165 0,33 -2,11 – 7,59 
LH peak (U/L) 476  21,87 ± 18,801 16,3 7 - 229 
LH peak/ FSH peak 465  1,44 ± 1,383 1,125 0,22 – 19,14 
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Figure 3: Baseline characteristics - Ethnic group  
 
 
Figure 4: Baseline characteristics - Autonomous community  
1,6
68,8
















































Table 4: Outcomes’ results 
 
 
Outcome N Mean ± SD Median Minimum - Maximum IC 95% 
NAH – TH (cm) 102 -1,033 ± 6.362 -1,225 -17,50 – 18,00 -2,293 - 0.227 
NAH SD – TH SD (cm) 102 -0,178 ± 1,112 -0,215 -3,06 – 3,15 -0,4 - 0,04 
NAH – PAH (cm) 126 -3,093 ± 7,012 -3,355 -20,19 – 11,91 -4,344 - -1.844 
NAH SD – PAH SD (cm) 126 -0,54 ± 1,225 -0,585 -3,53 – 2,08 -0,759 - -0.322 
NAH (cm) 132 156,48 ±7,073 156,6 137,00 – 183,00 155,26 - 157,72 
NAH SD (cm) 132 -0,822 ± 1,236 -0,81 -4,24 – 3,80 -1,037 - -0,607 
Treatment cessation height (cm) 283 144,88 ± 7,037 144,8 119,4 – 163,3 144,05 - 145,72 
Treatment cessation height SD 
(cm) 
283 -2,864 ± 1,231 -2,88 -7,32 – 0,36 -4,327 - -1,4 
NAH - Treatment cessation height 
(cm) 
130 11,27 ± 4,896 11,05 0 – 25,00 10,41 - 12,12 
NAH SD - Treatment cessation 
height SD (cm) 
130 1,98 ± 0,871 1,935 0 – 4,37 1,83 – 2,135 
Treatment cessation CA (years) 283 10,03 ± 1,004 10,055 7,09 – 12,77 9,91 - 10,15 
Treatment cessation BA (years) 240 11,67 ± 0,793 11,75 9,75 – 15 11,57 - 11,77 
Treatment duration (months) 282 29,82 ± 14,21 28,92 3,70 – 90 28,13 - 31,51 
Time between treatment cessation 
until menarche (months) 
210 13,14 ± 9,74 13,56 -34,72 – 49,04 11,79 - 14,48 
Treatment cessation BMI SD 283 1,089 ± 1,277 0,96 -1,58 – 5,25 0,94 - 1,24 
NAH BMI SD 124 0,925 ± 1,249 0,74 -2,26 - 4,95  0.70 - 1.15  
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Figure 7: Height’s (cm) continuous evolution  
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